



Integra LifeSciences Launches Integra(R) CUSA(R) NXT Bone Tips at 2012 American Association of Neurological Surgeons Annual Meeting

New Tips Expand Applications for CUSA(R) NXT Ultrasonic Tissue Ablation Systems

PLAINSBORO, N.J., April 16, 2012 (GLOBE NEWSWIRE) -- [Integra LifeSciences Holdings Corporation](#) (Nasdaq:IART) today announced the launch of the Integra[®] CUSA[®] NXT Bone Tips for Integra's CUSA[®] NXT Ultrasonic Tissue Ablation System. The CUSA[®] NXT system is a well-recognized medical device used in neurosurgical and other surgical procedures for the controlled and selective removal of soft tissue and bone near critical structures. The Integra[®] CUSA[®] NXT Bone Tips have received 510 (k) clearance from the United States Food and Drug Administration (FDA), and will be featured at the 2012 American Association of Neurological Surgeons (AANS) annual meeting, April 14 - 18, 2012, in Miami, Florida.

The new Integra[®] CUSA[®] NXT Bone Tips expand the surgical applications for the CUSA[®] NXT system. Driven by the CUSA[®] Selector[®] 24 kHz Neurosurgical Short handpiece, the Integra[®] CUSA[®] NXT Bone Tips allow surgeons to use ultrasonic tissue ablation in procedures requiring precise, controlled bone removal near critical structures where the rotational motion of a drill or frictional heat may be a concern.

The new Bone Tips feature a one-piece tip design, low profile silicone flue, and an ergonomic shroud, all single-use items packaged in a procedure pack. This simplifies handpiece set-up prior to the procedure and helps save valuable time in the operating room. "We are excited to expand the tip selection for Integra's CUSA[®] NXT platform," said Peter Colgan, Director, Tissue Ablation Marketing. "We can now help neurosurgeons limit uncertainty in surgical procedures where precise control and the ability to keep the surgical site cool during bone removal are important requirements."

Over 2,000 centers worldwide rely on the CUSA[®] ultrasonic surgical ablation technology for a variety of procedures, including the removal of tissues associated with brain and abdominal tumors. Integra currently offers a diverse line of CUSA[®] tissue ablation products, including the CUSA[®] NXT, CUSA[®] Excel+, CUSA[®] Excel, CUSA[®] Selector[®], and CUSA[®] Dissectron[™] systems.

[Integra LifeSciences](#), a world leader in medical devices, is dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care. Integra offers innovative solutions in orthopedics, neurosurgery, spine, reconstructive and general surgery. For more information, please visit www.integralife.com

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the products and services provided by Integra. Such forward looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of surgical professionals to use the products may affect the prospects for their use in surgical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the heading "Risk Factors" included in Item 1A of Integra's Annual Report on Form 10-K for the year ended December 31, 2011 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

CONTACT: Integra LifeSciences Holdings Corporation

Gianna Sabella

Director, Corporate Communications

(609) 936-2389

gianna.sabella@integralife.com